Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap.

Soler-Cataluña JJ, Novella L, Soler C, Nieto ML, Esteban V, Sánchez-Toril F, Miravitlles M.

Arch Bronconeumol. 2019 Nov 26. pii: S0300-2896(19)30392-8. doi: 10.1016/j.arbres.2019.08.023. [Epub ahead of print] English, Spanish.

2.

EVALUATION OF CHANGES IN CONTROL STATUS IN COPD: AN OPPORTUNITY FOR EARLY INTERVENTION: Control status is useful for clinical assessment.

Soler-Cataluña JJ, Alcazar B, Marzo M, Pérez J, Miravitlles M.

Chest. 2019 Nov 21. pii: S0012-3692(19)34222-9. doi: 10.1016/j.chest.2019.11.004. [Epub ahead of print]

PMID:
31759964
3.

Treatment with inhaled α1-antitrypsin: a square peg in a round hole?

Barrecheguren M, Miravitlles M.

Eur Respir J. 2019 Nov 21;54(5). pii: 1901894. doi: 10.1183/13993003.01894-2019. Print 2019 Nov. No abstract available.

PMID:
31754075
4.

Pulmonary Rehabilitation… Yes But No.

Pleguezuelos E, Miravitlles M.

Arch Bronconeumol. 2019 Dec;55(12):617-618. doi: 10.1016/j.arbres.2019.07.018. Epub 2019 Oct 29. English, Spanish. No abstract available.

5.

Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease.

Esquinas C, Ramon MA, Nuñez A, Molina J, Quintano JA, Roman-Rodríguez M, Naberan K, Llor C, Roncero C, Miravitlles M, Barrecheguren M.

Qual Life Res. 2019 Oct 31. doi: 10.1007/s11136-019-02340-4. [Epub ahead of print]

PMID:
31673922
6.

Non-eosinophilic severe exacerbations of COPD: what about antibiotics?

Miravitlles M, Llor C.

Lancet Respir Med. 2019 Nov;7(11):e33. doi: 10.1016/S2213-2600(19)30347-9. No abstract available.

PMID:
31645283
7.

Time To Revise COPD Treatment Algorithm.

Matsunaga K, Oishi K, Miravitlles M, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2019 Sep 27;14:2229-2234. doi: 10.2147/COPD.S219051. eCollection 2019.

8.

Geographic distribution of chronic obstructive pulmonary disease prevalence in Africa, Asia and Australasia.

Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1100-1106. doi: 10.5588/ijtld.19.0015.

PMID:
31627775
9.

Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?

Miravitlles M, Llor C, Bjerrum L, Sethi S, Anzueto A.

Eur Respir J. 2019 Oct 17;54(4). pii: 1901405. doi: 10.1183/13993003.01405-2019. Print 2019 Oct. No abstract available.

PMID:
31624129
10.

The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization.

Roche N, Anzueto A, Bosnic Anticevich S, Kaplan A, Miravitlles M, Ryan D, Soriano JB, Usmani O, Papadopoulos NG, Canonica GW; Respiratory Effectiveness Group Collaborators.

Eur Respir J. 2019 Sep 19;54(3). pii: 1901511. doi: 10.1183/13993003.01511-2019. Print 2019 Sep. No abstract available.

11.

Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study.

Kim KY, Miravitlles M, Sliwinski P, Costello R, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price D, Rhee CK.

Int J Chron Obstruct Pulmon Dis. 2019 Jul 25;14:1595-1601. doi: 10.2147/COPD.S208245. eCollection 2019.

12.

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms.

Avdeev S, Aisanov Z, Arkhipov V, Belevskiy A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2019 Jun 10;14:1267-1280. doi: 10.2147/COPD.S207775. eCollection 2019.

13.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges.

López-Campos JL, Soler-Cataluña JJ, Miravitlles M.

Arch Bronconeumol. 2019 Jul 15. pii: S0300-2896(19)30275-3. doi: 10.1016/j.arbres.2019.06.001. [Epub ahead of print] English, Spanish. No abstract available.

14.

Clinical Control in COPD: A New Therapeutic Objective?

Soler-Cataluña JJ, Alcázar B, Miravitlles M.

Arch Bronconeumol. 2019 Jul 10. pii: S0300-2896(19)30278-9. doi: 10.1016/j.arbres.2019.06.004. [Epub ahead of print] English, Spanish. No abstract available.

15.

Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices.

Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JFM, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, D'Urzo AD, Roche N.

Ann Am Thorac Soc. 2019 Sep;16(9):1143-1150. doi: 10.1513/AnnalsATS.201809-607OC.

PMID:
31162945
16.

Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population.

Janciauskiene S, DeLuca DS, Barrecheguren M, Welte T, Miravitlles M; Scientific Committee; Participating sites and coordinators.

Arch Bronconeumol. 2019 May 30. pii: S0300-2896(19)30112-7. doi: 10.1016/j.arbres.2019.03.001. [Epub ahead of print] English, Spanish.

17.

Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation.

Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Schneider CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, Siegmund B, Simões C, Gaspar R, Maia L, Costa D, Bento-Miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravitlles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffiths WJ, Trauner M, Krag A, Trautwein C, Strnad P; European Alpha1-Liver Study Group.

Gastroenterology. 2019 Sep;157(3):705-719.e18. doi: 10.1053/j.gastro.2019.05.013. Epub 2019 May 20.

PMID:
31121167
18.

Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps.

Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M.

Eur Respir J. 2019 Jul 18;54(1). pii: 1900610. doi: 10.1183/13993003.00610-2019. Print 2019 Jul. No abstract available.

PMID:
31000678
19.

Multidisciplinary Perspectives on the Importance of Physical Activity in COPD.

Miravitlles M, Troosters T, Janssens W, Ancochea J.

Arch Bronconeumol. 2019 Nov;55(11):551-552. doi: 10.1016/j.arbres.2019.03.010. Epub 2019 Apr 11. English, Spanish. No abstract available.

20.

Patients with Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care.

Alcázar Navarrete B, Ancochea Bermúdez J, García-Río F, Izquierdo Alonso JL, Miravitlles M, Rodríguez González-Moro JM, Soler-Cataluña JJ.

Arch Bronconeumol. 2019 Sep;55(9):478-487. doi: 10.1016/j.arbres.2019.02.020. Epub 2019 Apr 6. English, Spanish.

21.

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study.

Miravitlles M, Koblizek V, Esquinas C, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, Tudoric N, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Valipour A.

Respir Med. 2019 Apr;150:141-148. doi: 10.1016/j.rmed.2019.03.007. Epub 2019 Mar 21.

PMID:
30961941
22.

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study.

Almagro P, Martínez-Camblor P, Miravitlles M, Rodríguez-Carballeira M, Navarro A, Lamprecht B, Ramirez-Garcia Luna AS, Kaiser B, Alfageme I, Casanova C, Esteban C, Soler-Cataluña JJ, de-Torres JP, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Anto JM, Turner AM, Han MK, Langhammer A, Sternberg A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosío B, Ancochea J, Echazarreta A, Roche N, Burgel PR, Sin DD, Puhan MA, Soriano JB; 3CIA collaboration.

COPD. 2019 Feb;16(1):8-17. doi: 10.1080/15412555.2018.1484440. Epub 2019 Mar 14.

PMID:
30870059
23.

Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey.

Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG.

ERJ Open Res. 2019 Mar 11;5(1). pii: 00171-2018. doi: 10.1183/23120541.00171-2018. eCollection 2019 Feb.

24.

Practical Guide to the Identification and Diagnosis of Asthma-COPD Overlap (ACO).

Nuñez A, Sarasate M, Loeb E, Esquinas C, Miravitlles M, Barrecheguren M.

COPD. 2019 Feb;16(1):1-7. doi: 10.1080/15412555.2019.1575802. Epub 2019 Feb 21.

PMID:
30789039
25.

The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency.

Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, McElvaney NG, O'Hara K, Stolk J, Stockley RA, Turner A, Wilkens M, Greulich T; EARCO Clinical Research Collaboration; Members of the EARCO Clinical Research Collaboration.

Eur Respir J. 2019 Feb 14;53(2). pii: 1900138. doi: 10.1183/13993003.00138-2019. Print 2019 Feb. No abstract available.

PMID:
30765486
26.

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Hermosa JLR; EPOCONSUL Study.

PLoS One. 2019 Feb 12;14(2):e0212522. doi: 10.1371/journal.pone.0212522. eCollection 2019.

27.

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen MT, Whalen J, Buguth BS, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.

Respir Res. 2019 Jan 28;20(1):18. doi: 10.1186/s12931-019-0985-2.

28.

10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain -A Summary of the EPISCAN II Protocol.

Alfageme I, de Lucas P, Ancochea J, Miravitlles M, Soler-Cataluña JJ, García-Río F, Casanova C, Rodríguez González-Moro JM, Cosío BG, Sánchez G, Soriano JB.

Arch Bronconeumol. 2019 Jan;55(1):38-47. doi: 10.1016/j.arbres.2018.05.011. Epub 2018 Jul 7. English, Spanish.

29.

Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire.

Núñez A, Esquinas C, Barrecheguren M, Calle M, Casamor R, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 26;13:3837-3844. doi: 10.2147/COPD.S179402. eCollection 2018.

30.

Validation of clinical control in COPD as a new tool for optimizing treatment.

Soler-Cataluña JJ, Marzo M, Catalán P, Miralles C, Alcazar B, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 14;13:3719-3731. doi: 10.2147/COPD.S178149. eCollection 2018.

31.

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.

Respir Res. 2018 Nov 20;19(1):224. doi: 10.1186/s12931-018-0916-7. Erratum in: Respir Res. 2019 Jan 28;20(1):18.

32.

How whole-body vibration can help our COPD patients. Physiological changes at different vibration frequencies.

Pleguezuelos E, Casarramona P, Guirao L, Samitier B, Ortega P, Vila X, Carmen AD, Ovejero L, Moreno E, Serra N, Gomís M, Garnacho-Castaño MV, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3373-3380. doi: 10.2147/COPD.S165058. eCollection 2018.

33.

Geographical Distribution of COPD Prevalence in the Americas.

Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M.

COPD. 2018 Jun-Aug;15(4):317-325. doi: 10.1080/15412555.2018.1481936. Epub 2018 Oct 30.

PMID:
30375898
34.

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB.

BMJ Open. 2018 Oct 27;8(10):e022051. doi: 10.1136/bmjopen-2018-022051. Erratum in: BMJ Open. 2018 Dec 9;8(12):e022051corr1. BMJ Open. 2019 Jun 14;9(6):e022051corr2.

35.

Rebuttal From Drs Barrecheguren and Miravitlles.

Barrecheguren M, Miravitlles M.

Chest. 2018 Oct;154(4):752-753. doi: 10.1016/j.chest.2018.06.021. No abstract available.

PMID:
30290928
36.

COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.

Barrecheguren M, Miravitlles M.

Chest. 2018 Oct;154(4):749-751. doi: 10.1016/j.chest.2018.06.024. No abstract available.

PMID:
30290926
37.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

38.

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care.

Barrecheguren M, Monteagudo M, Miravitlles M.

NPJ Prim Care Respir Med. 2018 Sep 28;28(1):36. doi: 10.1038/s41533-018-0102-x.

39.

Ischiocrural Strength May Be a Better Prognostic Marker Than Quadriceps Strength in COPD.

Pleguezuelos E, Guirao L, Moreno E, Samitier B, Ortega P, Vila X, Garnacho-Castaño MV, Majó M, Ovejero L, Miravitlles M.

Lung. 2018 Dec;196(6):665-668. doi: 10.1007/s00408-018-0164-0. Epub 2018 Sep 21.

PMID:
30242510
40.

Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017).

Pleguezuelos E, Gimeno-Santos E, Hernández C, Mata MDC, Palacios L, Piñera P, Molina J, Chiner E, Miravitlles M.

Arch Bronconeumol. 2018 Nov;54(11):568-575. doi: 10.1016/j.arbres.2018.06.001. Epub 2018 Sep 18. English, Spanish.

41.

Prevalence of smoking in a psychiatric hospital and its relationship with respiratory symptoms and the prevalence of COPD.

Lores L, Monje A, Bergada M, Arellano E, Rodríguez-Larrea J, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2797-2804. doi: 10.2147/COPD.S165880. eCollection 2018.

42.

What have we learned from observational studies and clinical trials of mild to moderate COPD?

Barrecheguren M, González C, Miravitlles M.

Respir Res. 2018 Sep 17;19(1):177. doi: 10.1186/s12931-018-0882-0. Review.

43.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

44.

What We Talk about When We Talk about Exacerbations of Chronic Obstructive Pulmonary Disease.

Miravitlles M.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):2-4. doi: 10.1164/rccm.201807-1299ED. No abstract available.

PMID:
30092146
45.

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.

Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD.

Eur Respir J. 2018 Sep 15;52(3). pii: 1800328. doi: 10.1183/13993003.00328-2018. Print 2018 Sep. Review.

PMID:
30049739
46.

Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F.

Orphanet J Rare Dis. 2018 Jul 11;13(1):114. doi: 10.1186/s13023-018-0856-9. Review.

47.

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Rodriguez Hermosa JL; EPOCONSUL Study.

PLoS One. 2018 Jun 28;13(6):e0198777. doi: 10.1371/journal.pone.0198777. eCollection 2018. Erratum in: PLoS One. 2019 Feb 12;14(2):e0212522.

48.

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same?

Miravitlles M, Baek S, Vithlani V, Lad R.

Tuberc Respir Dis (Seoul). 2018 Jul;81(3):198-215. doi: 10.4046/trd.2018.0040. Epub 2018 Jun 19. Review.

49.

Diagnosis of alpha1-antitrypsin deficiency not just in severe COPD.

Nuñez A, Barrecheguren M, Rodríguez E, Miravitlles M, Esquinas C.

Pulmonology. 2018 Nov - Dec;24(6):351-353. doi: 10.1016/j.pulmoe.2018.05.005. Epub 2018 Jun 18.

50.

Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed.

Soriano JB, Lucas SJ, Jones R, Miravitlles M, Carter V, Small I, Price D, Mahadeva R; Respiratory Effectiveness Group.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800360. doi: 10.1183/13993003.00360-2018. Print 2018 Jul.

PMID:
29853490

Supplemental Content

Loading ...
Support Center